Key regions: Brazil, India, Australia, United States, United Kingdom
The Antiviral Drugs market in G7 has been witnessing significant growth in recent years.
Customer preferences: The demand for antiviral drugs has been increasing due to the rise in viral infections such as HIV, hepatitis, influenza, and others. The increasing prevalence of these diseases has led to a surge in demand for antiviral drugs, which has been a major factor driving the growth of the market. Additionally, the aging population in G7 countries has also contributed to the growth of the market, as older individuals are more susceptible to viral infections.
Trends in the market: The antiviral drugs market in G7 countries has been witnessing several trends in recent years. One of the major trends is the increasing adoption of combination therapies, which involves the use of two or more antiviral drugs to treat viral infections. Combination therapies have been found to be more effective in treating viral infections, and this has led to their increasing adoption in G7 countries. Another trend in the market is the increasing focus on research and development of new antiviral drugs. Several pharmaceutical companies are investing heavily in R&D to develop new and more effective antiviral drugs.
Local special circumstances: The antiviral drugs market in each G7 country has its unique set of circumstances. For instance, in the United States, the market is heavily regulated by the FDA, which has stringent requirements for the approval of new antiviral drugs. In Japan, there is a high demand for antiviral drugs due to the high prevalence of viral infections such as hepatitis. In Germany, the market is dominated by a few large pharmaceutical companies, which has led to limited competition.
Underlying macroeconomic factors: The growth of the antiviral drugs market in G7 countries is also influenced by several macroeconomic factors. For instance, the increasing healthcare expenditure in these countries has led to greater access to healthcare services, including antiviral drugs. Additionally, the increasing prevalence of viral infections has led to a greater focus on preventive measures, which has also contributed to the growth of the market. Furthermore, the increasing awareness about the benefits of antiviral drugs has led to greater demand for these drugs in G7 countries.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
